Tenax Therapeutics (TENX) EBIT (2010 - 2026)

Tenax Therapeutics has disclosed EBIT across 16 years of filings, most recently posting -$18.8 million for Q2 2026.

• In Q2 2026, EBIT fell 59.29% year-over-year to -$18.8 million; the TTM figure through Jun 2026 stood at -$68.6 million (down 95.79% YoY), while the FY2025 annual figure was -$56.4 million, down 189.24% from the prior year.
• EBIT came in at -$18.8 million for Q2 2026 at Tenax Therapeutics, down from -$16.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $2.9 million in Q3 2022 to a low of -$18.8 million in Q2 2026.
• Average EBIT over 5 years is -$6.2 million, with a median of -$4.3 million recorded in 2024.
• Year-over-year, EBIT surged 104.1% in 2022 and plunged 613.85% in 2023.
• Over 5 years, EBIT stood at $2.6 million in 2022, then sank by 613.85% to -$13.1 million in 2023, then surged by 44.43% to -$7.3 million in 2024, then tumbled by 125.48% to -$16.4 million in 2025, then slipped by 14.2% to -$18.8 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$18.8 million in Q2 2026, -$16.6 million in Q1 2026, and -$16.4 million in Q4 2025.